Related references
Note: Only part of the references are listed.Correlation of Mutation Status and Survival with Predominant Histologic Subtype According to the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Stage III (N2) Patients
Prudence A. Russell et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis
Yang Zhang et al.
CLINICAL CANCER RESEARCH (2012)
High Incidence of EGFR Mutations in Korean Men Smokers with No Intratumoral Heterogeneity of Lung Adenocarcinomas Correlation with Histologic Subtypes, EGFR/TTF-1 Expressions, and Clinical Features
Ping-Li Sun et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Histopathologic Characteristics of Lung Adenocarcinomas With Epidermal Growth Factor Receptor Mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification
Hyo Sup Shim et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2011)
The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Share Paper
